John Berriman
Non-Executive Chairman
Management
Autifony Therapeutics
Italy
Biography
John Berriman is the Chairman of Heptares Therapeutics Ltd and past Chairman (now deputy Chairman) of Algeta ASA (OSE.ALGETA). He is also a non-executive director of Cytos AG (SW.CYTN) and ReNeuron Group PLC (L.RENE). Until its sale to Amgen in the spring of 2012 he was a director of MicroMet, Inc. (NASDAQ.MITI). Previously he was a director of Abingworth Management, an international healthcare venture capital firm, where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA, many of which obtained listings on public stock exchanges. Prior to that, he spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.
Research Interest
Chemical Engineering
